Salud financiera de hoja de balance de NeuroMetrix

Salud financiera controles de criterios 6/6

NeuroMetrix tiene un patrimonio de los accionistas total de $16.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $17.2M y $1.2M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$14.83m
Patrimonio	US$15.98m
Total pasivo	US$1.21m
Activos totales	US$17.19m

Actualizaciones recientes sobre salud financiera

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

Recent updates

NeuroMetrix reports Q3 results

Oct 20

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Sep 09

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($16.8M) de NURO superan a sus pasivos a corto plazo ($1.2M).

Pasivo a largo plazo: NURO no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: NURO está libre de deudas.

Reducción de la deuda: NURO no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NURO tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: NURO dispone de suficiente cash runway para 2.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 30.5% cada año.

Salud financiera de hoja de balance de NeuroMetrix

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Recent updates

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023)

NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

New major risk - Shareholder dilution

RS Fund Discloses its Views on NeuroMetrix

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

New minor risk - Share price stability

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix reports Q3 results

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Senior VP recently sold US$528k worth of stock

Senior VP recently sold US$271k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: US$3.76

New 90-day high: US$3.05

New 90-day high: US$1.86

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - US$1.72

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway